Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZZ2 | ISIN: US2666055007 | Ticker-Symbol: DC8A
Tradegate
27.03.24
21:04 Uhr
1,220 Euro
+0,020
+1,67 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DURECT CORPORATION Chart 1 Jahr
5-Tage-Chart
DURECT CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
1,1901,25010:48
1,1901,25010:15

Aktuelle News zur DURECT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiDURECT Corp reports results for the quarter ended in December - Earnings Summary2
MiDURECT Corp. Q4 Loss decreases, beats estimates-
MiDurect: Q4 Earnings Insights1
MiDURECT GAAP EPS of -$0.10 beats by $0.26, revenue of $2.67M misses by $0.03M1
DiDurect's Earnings: A Preview2
FrDURECT CORP - 8-K, Current Report2
04.03.DURECT CORP - 8-K, Current Report3
04.03.DURECT and Charles River enter agreement for alzet in U.S., Canada5
04.03.DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line3
04.03.DURECT Corporation: DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET Product Line in U.S. and Canada90Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly...
► Artikel lesen
22.12.23DURECT CORP - 8-K, Current Report4
14.11.23Earnings call: DURECT reports Q3 2023 financial results, positive clinical trial results12
13.11.23DURECT Corp reports results for the quarter ended in September - Earnings Summary3
13.11.23Recap: Durect Q3 Earnings2
13.11.23DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update147- Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET - Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality...
► Artikel lesen
10.11.23Durect Earnings Preview2
08.11.23HC Wainwright downgrades DURECT to neutral, removes price target11
08.11.23Why Is Pain & Liver Disease Focused DURECT Stock Plunging Today?11
08.11.23Durect, Lumos Pharma among healthcare movers8
08.11.23Durect fails alcohol-associated hepatitis trial, plans phase 3 anyway as investors scorch stock7
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1